Gewinn- und Verlustrechnung von Carpenter Technology Corporation

Carpenter (CRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Carpenter (CRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

PHILADELPHIA, July 01, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) plans to host a conference call and webcast on Thursday, July 30, 2026 at 10:00 a.m. ET to discuss the results of operations for the fourth quarter of fiscal year 2026, ended June 30, 2026.

Carpenter (CRS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Does Carpenter Technology (CRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Advancing financing partner alignment for BTC Structured Income Program; in active discussions on a pilot transaction with a major U.S. insurer for Credit Rating Securities Toronto, Ontario and New York, New York--(Newsfile Corp. - June 23, 2026) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF)  ("DelphX" or the "Company") today provided a corporate update on two of its principal commercialization workstreams. BTC Structured Income Program - Financing Partner Alignment The Company is pleased to report that it has finalized and executed a definitive agreement with a leading global digital asset lender - recognized as one of the most active and established credit providers in the cryptocurrency sector - for the senior secured lending facility that forms the foundational layer of capital for the Company's BTC Structured Income Program (the "Program").

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Shares in PPoolbeg Pharma PLC (AIM:POLB) rose 3% to 7.8p on Tuesday, taking their gain for the year to date to around 100%, after the drug developer secured a key European patent. The European Patent Office has agreed to grant a patent covering POLB 001, Poolbeg's experimental treatment for preventing cytokine release syndrome (CRS), a dangerous immune reaction triggered by some cancer immunotherapies.

PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Adstra Nonprofit today announced a strategic partnership with Catholic Relief Services (CRS), one of the world's leading humanitarian organizations.